DGAP-News

MOLOGEN AG: dSLIM(R) shows superior immunoactivation capabilities

DGAP-News: MOLOGEN AG / Key word(s): Study
MOLOGEN AG: dSLIM(R) shows superior immunoactivation capabilities

08.04.2014 / 15:19

---------------------------------------------------------------------

MOLOGEN AG: dSLIM(R) shows superior immunoactivation capabilities

Berlin, April 08, 2014 - MOLOGEN AG has presented latest research results
on its immunomodulator and TLR9 agonist dSLIM(R) in a poster presentation
at the American Association for Cancer Research (AACR) 2014 Meeting in San
Diego. The results show that the unique conformation of MOLOGEN's dSLIM(R)
molecule leads to superior cancer-fighting immunoactivation compared to
other TLR9 agonists.

DNA-based TLR9 agonists are potent activators of immune cell populations
and the immune system. The poster presentation reported results from a
comparison of dSLIM(R) with a different TLR9 agonist, representing the
classes of TLR9 agonists with linear DNA molecules.

dSLIM(R) establishes a new class of TLR9 agonists, represented by
covalently closed dumbbell-like DNA molecules consisting entirely of
natural DNA components with two single-stranded CG-containing loops
separated by a double-stranded stem. In contrast to dSLIM(R), all known
classes of TLR9 agonists are made of linear DNA molecules containing
non-natural DNA modifications.

dSLIM(R) is the active ingredient of the drug candidate MGN1703 currently
developed by MOLOGEN in oncology. In 2013 MGN1703 reported positive phase
II data in colorectal cancer (CRC) and this year a phase III is planned in
the same indication. Recently, a randomized study in small cell lung cancer
started patient accrual.

Poster Details:
Poster at the AACR-Meeting 2014 (poster abstract # 2565)
"Conformation overrides base sequence - insights from novel class TLR9
agonists" - Kerstin Kapp1, Matthias Schroff1, Burghardt Wittig2, Christiane
Kleuss1 (1Mologen AG, Berlin, Germany, 2Foundation Institute Molecular
Biology and Bioinformatics, Freie Universität Berlin, Germany)

About MGN1703
MGN1703 is based on dSLIM(R) ("double Stem Loop Immunomodulator"), an
innovative DNA-based TLR9 agonist developed by MOLOGEN. dSLIM(R) activates
the immune system against tumor-associated antigens by targeting various
receptors on certain immune cells, primarily TLR9. Tumor-associated
antigens (TAA) are released by cancer cells as a result of chemotherapy and
radiation therapy. Once activated by dSLIM(R), the immune system is able to
overcome its fatal tolerance toward cancer cells and TAA and attacks them